Kolinsky Wealth Management LLC Has $603,000 Holdings in Abbott Laboratories (NYSE:ABT)

Kolinsky Wealth Management LLC increased its holdings in shares of Abbott Laboratories (NYSE:ABT) by 4.8% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 5,334 shares of the healthcare product maker’s stock after purchasing an additional 242 shares during the quarter. Kolinsky Wealth Management LLC’s holdings in Abbott Laboratories were worth $603,000 as of its most recent SEC filing.

Other hedge funds have also added to or reduced their stakes in the company. Cape Investment Advisory Inc. boosted its position in Abbott Laboratories by 6.6% during the fourth quarter. Cape Investment Advisory Inc. now owns 1,236 shares of the healthcare product maker’s stock valued at $140,000 after purchasing an additional 76 shares during the last quarter. Capital Square LLC grew its stake in shares of Abbott Laboratories by 2.7% in the fourth quarter. Capital Square LLC now owns 2,941 shares of the healthcare product maker’s stock valued at $368,000 after buying an additional 77 shares in the last quarter. Cyrus J. Lawrence LLC increased its holdings in Abbott Laboratories by 9.0% during the fourth quarter. Cyrus J. Lawrence LLC now owns 954 shares of the healthcare product maker’s stock worth $107,000 after buying an additional 79 shares during the last quarter. LMG Wealth Partners LLC raised its position in Abbott Laboratories by 3.8% during the fourth quarter. LMG Wealth Partners LLC now owns 2,161 shares of the healthcare product maker’s stock worth $244,000 after acquiring an additional 80 shares in the last quarter. Finally, Jacobson & Schmitt Advisors LLC grew its position in shares of Abbott Laboratories by 2.9% in the 4th quarter. Jacobson & Schmitt Advisors LLC now owns 2,827 shares of the healthcare product maker’s stock valued at $320,000 after acquiring an additional 80 shares during the period. Institutional investors own 75.18% of the company’s stock.

Insider Buying and Selling

In other news, Director Sally E. Blount sold 2,600 shares of the company’s stock in a transaction dated Wednesday, April 30th. The shares were sold at an average price of $129.66, for a total transaction of $337,116.00. Following the transaction, the director now owns 34,058 shares in the company, valued at approximately $4,415,960.28. This represents a 7.09% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Eric Shroff sold 562 shares of the business’s stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $138.17, for a total value of $77,651.54. Following the completion of the sale, the senior vice president now directly owns 31,970 shares of the company’s stock, valued at $4,417,294.90. The trade was a 1.73% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 95,278 shares of company stock valued at $12,745,859 over the last ninety days. 0.46% of the stock is owned by corporate insiders.

Abbott Laboratories Price Performance

ABT stock opened at $135.18 on Wednesday. The company has a quick ratio of 1.14, a current ratio of 1.60 and a debt-to-equity ratio of 0.32. The firm has a market cap of $235.19 billion, a price-to-earnings ratio of 17.67, a PEG ratio of 2.52 and a beta of 0.74. The company’s fifty day simple moving average is $129.57 and its 200 day simple moving average is $124.37. Abbott Laboratories has a 12-month low of $99.71 and a 12-month high of $141.23.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings data on Wednesday, April 16th. The healthcare product maker reported $1.09 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.07 by $0.02. The company had revenue of $10.36 billion for the quarter, compared to the consensus estimate of $10.38 billion. Abbott Laboratories had a return on equity of 20.74% and a net margin of 31.95%. On average, analysts expect that Abbott Laboratories will post 5.14 earnings per share for the current year.

Abbott Laboratories Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Thursday, May 15th. Investors of record on Tuesday, April 15th were given a dividend of $0.59 per share. The ex-dividend date of this dividend was Tuesday, April 15th. This represents a $2.36 dividend on an annualized basis and a dividend yield of 1.75%. Abbott Laboratories’s payout ratio is presently 30.61%.

Analysts Set New Price Targets

Several brokerages have recently commented on ABT. Wells Fargo & Company lifted their target price on Abbott Laboratories from $136.00 to $147.00 and gave the stock an “overweight” rating in a research note on Thursday, April 17th. Barclays raised their target price on shares of Abbott Laboratories from $158.00 to $159.00 and gave the stock an “overweight” rating in a report on Thursday, April 17th. Argus raised shares of Abbott Laboratories to a “strong-buy” rating in a research report on Tuesday, January 28th. Piper Sandler reaffirmed an “overweight” rating and issued a $145.00 target price (up previously from $133.00) on shares of Abbott Laboratories in a report on Thursday, April 17th. Finally, UBS Group upped their price objective on shares of Abbott Laboratories from $146.00 to $148.00 and gave the stock a “buy” rating in a research report on Thursday, January 23rd. Four analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $142.59.

Abbott Laboratories Company Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.